AbbVie Cancer Drug Approved for CDF Coverage in UK

UK drug regulators approved venetoclax for coverage through the Cancer Drugs Fund of the National Health Service.

The drug is marketed by AbbVie as Venclyxto.

Venclyxto was approved for treating chronic lymphocytic leukemia in adults.